Structure Therapeutics Inc. Stock News

Structure Therapeutics is developing a potentially powerful weight loss medicine. That medicine may end up being more effective than Novo Nordisk's offerings.

Ray Stevens, Structure Therapeutics CEO, joins 'Fast Money' to discuss the weight loss drug boom and the company's recent data finidngs in its own drug.

Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.

Structure Therapeutics is a clinical-stage biotech developing a small-molecule drug that mimics an important gut hormone. Early results for Structure Therapeutics' lead candidate compare well with Weg

Structure Therapeutics published some strong data from its weight-loss program. Its candidate preliminarily appears to be more effective than the market leader.

SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met

SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met

Undervalued biotech stocks can offer some of the most explosive opportunities. That is, if you can spot the right one at the right time.

Jared Holz, Mizuho, joins 'Fast Money' to talk Structure Therapeutics soaring on its GLP-1 data and M&A targets in the obesity drug space.

SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met

Structure Therapeutics (NASDAQ: GPCR ) stock is surging today, up 60% after the biotech company reported promising results of its mid-stage trials for its weight loss pills. Indeed, after 12 weeks, pa

Structure Therapeutics stock roses sharply Monday after the biotech company delivered "compelling" results for its weight-loss drug.

Structure Therapeutics Inc.'s American depositary receipts GPCR, +1.30% gained more than 6% premarket on Monday after the company said its experimental weight-loss pill achieved its aims in a clinical

GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p

Sometimes the next big thing stocks to buy and hold are flying well under the radar. Look at Apple (NASDAQ: AAPL ).